At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
NiCord®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
In Brief
A Phase 2 clinical trial evaluating NiCord® for Hematological Malignancies and 3 related conditions. Completed, enrolled 36 participants across 15 sites in 5 countries.
Detailed Summary
A Study Evaluating the Safety and Efficacy of Transplantation of a single cord blood unit (CBU) of NiCord®, umbilical cord blood-derived Ex Vivo Expanded Stem and Progenitor Cells in Patients with Hematological Malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
CountriesItaly, Netherlands, Singapore, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartApr 2013
Primary CompletionJun 2017
Study CompletionJun 2018
TodayJul 2026
First PostedMar 22, 2013
Enrollment StartApr 1, 2013
Primary CompletionJun 1, 2017
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 13.3 years ago
Interventions
NiCord®drug